An announcement from Uniphar PLC ( (GB:UPR) ) is now available.
Uniphar PLC reported strong financial results for 2024, with a 12% growth in Adjusted EPS and a 15.2% ROCE, driven by robust organic growth across its divisions. The company achieved a gross profit growth of 9.6% and an EBITDA increase of 6.4%, reflecting successful strategic execution and investment for future growth. Uniphar’s strategic initiatives, including a share buyback program and capital investments in a new distribution facility, position it well for future expansion. The company remains on track to achieve its target of €200m EBITDA by 2028, with a significant portion of growth expected to be organic, reinforcing its strong market positioning and operational excellence.
More about Uniphar PLC
Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business that serves over 200 multinational pharmaceutical and medical technology manufacturers through its three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company operates in Europe, North America, APAC, and MENA, delivering to more than 160 countries. Uniphar aims to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders.
YTD Price Performance: 17.54%
Average Trading Volume: 30,541
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £539.1M
For a thorough assessment of UPR stock, go to TipRanks’ Stock Analysis page.